NunaBio is a privately owned life sciences company based in the northeast of the UK. Founded in 2021, our multi-patented technology can quickly produce large quantities of pure synthetic DNA using environmentally conscious processes.
NunaBio is developing a novel method of DNA synthesis which enables the cost-effective production of oligonucleotides at impressive scale, speed and accuracy. The platform will enable synthesis of whole genes and DNA fragments of unprecedented length without the use of plasmids or primers, which are existing bottlenecks in the synthetic biology industry.
NunaBio’s technology has broad applications across multiple areas of life sciences, including gene therapy, T cell engineering, viral vector synthesis, hybridisation capture and targeted biomarker panels.
Our mission is to enable game changing technologies across the life sciences and biotech sectors by providing novel high-quality material at scale – we are not only making products, we are empowering the most cutting-edge technologies to make an impact on the world.
For further information on NunaBio visit www.nunabio.com